AskBio acquires BrainVectis to expand its gene therapy portfolio
Category: #world  By Pankaj Singh  Date: 2020-04-23
  • share
  • Twitter
  • Facebook
  • LinkedIn

AskBio acquires BrainVectis to expand its gene therapy portfolio

Asklepios BioPharmaceutical, Inc. (AskBio), a prominent U.S.-based clinical-stage AAV gene therapy firm, has recently announced that it has acquired BrainVectis, a Paris-based gene therapy firm renowned for its work in neurodegenerative disorders, especially on therapies that regenerate brain cholesterol metabolism for patients suffering from Huntington's disease along with other disorders.

For the record, BrainVectis was initiated by Nathalie Cartier-Lacave, M.D., and has support and funding from Sorbonne University, the French Alternative Energies, and INSERM. Currently, Dr. Cartier-Lacave of Atomic Energy Commission (CEA) and her team are concentrating on developing gene therapies that increase the CYP46A1 enzyme’s expression in the brain.

Evidently, this enzyme is associated with numerous disorders where brain cholesterol metabolism dysfunction is concerned in the neurodegeneration’s pathology.

Sources cite that AskBio would leverage BrainVectis’ synthetic and capsid promotor design platforms and its capacity to advance the development of this platform and manufacturing solutions along with other BrainVectis projects.

Speaking on the move, Sheila Mikhail, CEO and Co-Founder, AskBio, said that the company’s acquisition of BrainVectis provides it with a remarkable opportunity to work jointly while transforming patients’ lives.

Huntington's disease is one of the diseases that is irreversible and devastating and presently has no effective treatments. However, BrainVectis’ in-depth world-leading knowledge of neurodegenerative diseases including Huntington’s disease could allow AskBio to expand its portfolio for these diseases as well.

Prior to this news, AskBio had made headlines when it revealed that it has appointed Don Haut, Ph.D., as its new Chief Business Officer to handle business development execution and strategy.

Reportedly, Dr. Haut has over two decades of healthcare experience and was previously serving to Histogenics Inc. and Sherlock Biosciences as their Chief Business Officer.

Commenting on which, Mikhail said that Don would be a key addition to the company as he holds a wealth of business and strategy development experience within the medical technology and biotechnology fields. His expertise would help the company to effectively advance its existing platforms.

Source Credit: https://www.contractpharma.com/contents/view_breaking-news/2020-04-22/askbio-acquires-brainvectis/



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Appili gets FDA approval to expand the clinical trial of favipiravir
Appili gets FDA approval to expand the clinical trial of favipiravir
By Pankaj Singh

Biopharmaceutical major, Appili Therapeutics Inc., has reportedly announced that it has received the approval of the U.S. Food and Drug Administration (FDA) over its recently filed investigational new drug application ...

Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
Saudi begins Phase III clinical trials of Chinese COVID-19 vaccine
By Pankaj Singh

The Ministry of Health, Saudi Arabia, has reportedly announced that it will begin the third phase of clinical trials for a COVID-19 vaccine, as part of its cooperation with China’s CanSino Biologics Inc. The tria...

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...